UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the Securities
Exchange
Act of 1934
Filed by
the Registrant ¨
Filed by
a Party other than the Registrant x
Check the
appropriate box:
|
¨
|
Preliminary
Proxy Statement
|
|
¨
|
Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
¨
|
Definitive
Proxy Statement
|
|
x
|
Definitive
Additional Materials
|
|
¨
|
Soliciting
Material Pursuant to §240.14a-12
|
The
Quigley Corporation
(Name of
Registrant as Specified In Its Charter)
Ted
Karkus
Mark
Burnett
John
DeShazo
Mark
Frank
Louis
Gleckel, MD
Mark
Leventhal
James
McCubbin
(Name of
Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
x
No fee
required.
¨
Fee computed
on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title
of each class of securities to which transaction
applies:
|
| |
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
| |
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
|
| |
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
| |
|
|
| o |
Fee
paid previously with preliminary materials. |
| |
|
|
¨
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its
filing.
|
|
|
(1)
|
Amount
Previously Paid:
|
|
|
(2)
|
Form,
Schedule or Registration Statement
No.:
|
FOR
FURTHER INFORMATION:
Ted
Karkus
Phone:
(516) 569-9999
Paul
Schulman
The
Altman Group, Inc.
Phone:
(201) 806-2206
FOR
IMMEDIATE RELEASE
TUESDAY,
MAY 19, 2009
IN
ELEVENTH-HOUR SMEAR ATTEMPT, QUIGLEY MANAGEMENT SACRIFICES KEY EMPLOYEE OF ITS
PHARMA DIVISION
Woodmere, NY – May 19, 2009 – In an
eleventh-hour attempt to smear Ted Karkus, The Quigley Corporation
(NASDAQ: QGLY) has issued a press release claiming that there was some improper
financial arrangement between Dr. Richard Rosenbloom, a key staff member of a
subsidiary of Quigley, and Mr. Ted Karkus, who leads a group of dissident
shareholders who have offered their own slate of Quigley’s Board of Directors
for election at the annual meeting scheduled for Wednesday, May 20,
2009.
Mr.
Karkus had loaned Dr. Rosenbloom a total of $55,000 over a period of
approximately six months. The loans were sought by Dr. Rosenbloom for
personal purposes. They are reflected in a written promissory note
that provides, appropriately, for repayment of the loan and the payment of
interest, and are secured by other assets of Dr. Rosenbloom.
Mr.
Karkus did not seek, nor did he receive, any “inside information” in connection
with the loan or otherwise.
Mr.
Karkus has stated: “I am proud to have been in a position to help out someone in
need. For the Company to attempt to manufacture a scandal on the last day
of voting is disgraceful. It is quite obvious that they knew about this
loan before today, and for the Company to treat Richard Rosenbloom so
disgracefully is truly reprehensible.”
Quigley
has apparently determined to suspend, and perhaps discharge, Dr. Rosenbloom as a
result of his alleged failure to report the loans to the CEO, Mr. Guy
Quigley. Putting aside the question of what right Mr. Guy Quigley had
to demand reports of this kind, the willingness of The Quigley Corporation to
sacrifice Dr. Rosenbloom in an effort to impugn Mr. Karkus must be of
grave concern to all shareholders. As the Company just stated in its
Form 10-K, filed on March 9, 2009:
The
Company’s Future Success Depends on the Continued Employment of Richard A.
Rosenbloom, M.D., Ph.D., with Pharma. Pharma’s potential new products
are being developed through the efforts of Dr. Rosenbloom. The loss
of his services could have a material adverse effect on the Company’s product
development and future operations.
In short,
Mr. Guy Quigley is willing to subject your Company to this possible material
adverse effect and to jeopardize the Company’s product development and future
operations, all in the name of avoiding a loss of control.
Quigley
has loosely alluded to discovery responses made by Mr. Ted Karkus in recent
litigation that Quigley began against him and other members of the his group
(but, notably, that Quigley has since voluntarily abandoned). The
Company’s discovery was focused on officers and directors of The Quigley
Corporation. Dr. Rosenbloom is neither an officer nor director of the
Quigley Corporation and instead is on the staff of a wholly-owned
subsidiary. Whatever else may be made of the record of the
now-dismissed action, there is no proper basis for any claim of
impropriety.
Unfortunately,
the entire affair reveals the lengths that entrenched management will go, and
the injury they are willing to inflict on both a key staff member of the Pharma
subsidiary and the Company’s overall interests, in order to stay in
office.
The
Karkus group respectively urges the shareholders to replace the Board of
Directors on May 20, 2009, and elect directors that will put the interests of
the Company and its shareholders first.
VOTING
INSTRUCTIONS:
Only your last vote counts.
Simply find the control # on our lightly shaded Blue Voting Instruction Form.
This is the voting form that has the Ted Karkus list of Shareholder Nominees on it.
Then call (800) 454-8683 or go to www.proxyvote.com and input your control #
when prompted. It is that simple to vote or to change your vote.
You may
also call the Shareholder Nominees' proxy solicitor, The Altman Group, toll free
at (866) 796-7175, if you have any questions or need assistance. Finally, Mr.
Karkus welcomes all calls to discuss the Company and its future with any or
shareholders. He is available at (516) 569-9999.
Important Additional
Information
Ted
Karkus, Mark Burnett, John DeShazo, Mark Frank, Louis Gleckel, MD, Mark
Leventhal and James McCubbin (the "Shareholder Nominees") filed a definitive
proxy statement with the Securities and Exchange Commission (the "SEC") on May
1, 2009 in connection with the 2009 Annual Meeting of Stockholders of The
Quigley Corporation. Stockholders are strongly advised to read the Shareholder
Nominees' proxy statement as it contains important information. Stockholders may
obtain an additional copy of the Shareholder Nominee's definitive proxy
statement and any other documents filed by them with the SEC for free at the
SEC's website at http://www.sec.gov. Additionally, copies of the
definitive proxy statement are available for free at
www.shareholdermaterial.com/qgly.
CONTACT
INFORMATION:
Ted
Karkus
Phone:
(516) 569-9999
Paul
Schulman
The
Altman Group, Inc.
Phone:
(201) 806-2206